Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Bersacapavir (JNJ-56136379) and Itraconazole in Healthy Adults
NCT03945539Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bersacapavir in Chronic Hepatitis B (CHB), sponsored by Janssen Pharmaceutical. Primary endpoints: Area Under the Plasma Analyte Concentration Versus Time Curve (AUC [0-72 hours]) at Day 41, Area Under the Plasma Analyte Concentration Versus Time Curve (AUC [0-408 hours]) at Day 55 and 1 more. Started May 2019; status: completed.
02
Drugs
bersacapavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03945539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03945539.